H:\rec\Internoven\NRPortbl\DCC\REC\6258927_I.doc-30/04/2014 H:\rec\Interwoven\NRPortbI\DCC\REC6258927_1.doc-30/04/2014
2016202063 04 Apr 2016 04 Apr 2016
NOVEL PHARMACEUTICAL NOVEL COMPOSITION PHARMACEUTICAL COMPOSITION
This is This is aa divisional divisionalofofAustralian AustralianPatent PatentApplication ApplicationNo. No.2014202367, the entire 2014202367, the entire contents of contents of which are incorporated which are herein by incorporated herein by reference. reference.
FIELD OF FIELD OF THE THE INVENTION INVENTION 2016202063
The present The present invention invention relates relates to to granules granules and and solid solidoral oralpharmaceutical pharmaceutical dosage dosage
forms,suitably forms, suitablytablets, tablets,suitably suitably capsules, capsules, comprising comprising 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-
dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3 dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidenelhydrazino]-2-hydroxy-[1,1'-biphenyl]-3-
carboxylic acid carboxylic acid bis-(monoethanolamine) represented bis-(monoethanolamine) represented by by thethe following following formula formula (1) (1) andand
hereinafter hereinafter referred referredtotoasas"eltrombopag "eltrombopag olamine" or Compound olamine" or Compound B: B:
C0 2H CO2H
OH OH NH N NH N N 0 HO~> ) -N 0 HO NH 2
N-N
(CompoundB). (Compound B).
BACKGROUNDOFOF BACKGROUND THE THE INVENTION INVENTION 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-
ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic ylidene]hydrazino}-2-hydroxybiphenyl-3-carboxylic acid acid (hereinafter (hereinafter Compound Compound A) A) is a is a compound compound which which is disclosed is disclosed and and claimed, claimed, along along with with pharmaceutically pharmaceutically acceptable acceptable salts, salts,
hydrates, solvatesandand hydrates, solvates esters esters thereof, thereof, as being as being useful useful as an as an agonist agonist of the of TPOthe TPO receptor, receptor,
particularly inenhancing particularly in enhancing platelet platelet production production and particularly and particularly in in
- 1-
04 Apr 2016
the the treatment thrombocytopenia, treatment ofofthrombocytopenia, in International in International Application Application No. No. PCT/US01/16863, having PCT/US0i/16863, an International having filingfiling an International date of Mayof date May 24, 2001; 2001; International 24,International Publication Number WO 01/89457 Publication Number WO 01/89457 and an International and an International Publication Publication date of date of November November29, 29,2001; whichhas 2001;which Publication Number States Publication UnitedStates hasUnited US2004/0019190 Number US2004/0019190
55 AI, Al, having a United StatesStates having a United Publication date ofdate Publication of January January 29,now2004; 29, 2004; now United United States States
Patent No. Patent No.7,160,870, issued 7,160,870,issued January January 9, 2007, the the 9, 2007, disclosure disclosure of which of which is hereby is hereby 2016202063
reference. incorporatedbybyreference. incorporated
The Thebis-(monocthanolamine) bis-(monoethanolamine)salt of of this saltthis compound compound is disclosed is disclosed (disclosed (disclosed as as
3'-[(2Z)-[ -(3,4-dimethylphenyl)- 1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazal-4-
ylidene]hydrazino]-2'-hydroxy- 1,1 '-biphenyl]-3-carboxylicacid, 10 ylidene]hydrazino]-2-hydroxy-[1,l'-biphenyl]-3-carboxylic 10 also which also acid, which describes Compound A)A)ininInternational describes Compound No. PCT/USO3/16255, ApplicationNo. International Application having PCT/US03/16255, having
an an International filing date International filing of May date of 2003; May21,21,2003; International International Publication Publication Number Number WO WO an an 03/098002andand 03/098002 International International Publication date date Publication of December of December 4, which 4, 2003; which 2003;has has United Number US2006/0178518 PublicationNumber States Publication United States A 1, US2006/0178518 A1, havinga aUnited having States UnitedStates 15 date date Publication 15 Publication of August of August 10, 2006; 10, 2006; the disclosure the disclosure of which hereby incorporated herebyis incorporated ofiswhich reference. by reference. by
is disclosed Compound A isAdisclosed Compound for the the treatment for treatment of degenerative of degenerative diseases/injuries discases/injuries
in International in International Application PCT/USO4/013468, No.PCT/US04/013468, ApplicationNo. having having an an International International filing filing date of date 29, 2004; April 29, of April Number PublicationNumber InternationalPublication 2004;International WO 04/096154 WO 04/096154 and an and an 20 InternationalPublication 20 International of November date of Publication date November 11, whichhas 2004; which I1,2004; States United States hasUnited Publication Number Publication US2007/0105824 Number US2007/0105824 A1,Al, having having a United a United States date Publication date StatesPublication May10,10,2007; of May of thethe 2007; disclosure of of disclosure which which is hereby is hereby incorporated incorporated by reference. by reference.
that may Compositions that Compositions may contain Compound A A contain Compound and/or Compound and/orCompound B B are are disclosed inin International disclosed ApplicationNo.No. International Application PCT/US01/16863, PCT/US01/16863, International International
No.No. Application 25 Application 25 PCT/USO3/16255 PCT/US03/16255 and International and International Application No. No. Application PCT/USO4/0 13468. PCT/US04/013468.
oral pharmaceutical Solid oral Solid dosage pharmaceuticaldosage forms forms are popular are popular and useful forms forms and useful of of dispensing medicationsforfordispensing medications pharmaceutically pharmaceutically active active compounds. compounds. Aofvariety A variety such of such forms known, areknown, formsare including including tablets, tablets, capsules, capsules, pellets, pellets, lozenges, and and lozenges, powders. powders.
30 formulation However,thetheformulation However, of an oral oral solidsolid an acceptable of acceptable pharmaceutical dosage dosage pharmaceutical 30 commercial formonona acommercial form scale scale is not is not always always straightforward. straightforward. The formula The formula and and process process of manufacture of must manufacture must suchsuch be be as to to provide as provide an integral an integral solid solid dosage dosage form form that that
-2-
04 Apr 2016
maintains its maintains until used. integrity until its integrity Thesolid used. The dosage soliddosage form form must also also must possess possess
acceptable dissolution and acceptable dissolution anddisintegration properties disintegrationproperties to to as as SO so provide the the provide desired desired
profile in use. Pharmaceutically active profile in use. Pharmaceutically compounds compounds active with low and/or and/or low solubility withsolubility that that can react with commonly usedused can react with commonly excipients excipients can present can present particular particular challenges challenges in in 5 preparing high quality solid dosage 5 preparing high quality solid forms,forms, dosage since since the the physical physical properties properties of the of the drug drug influence the influence propertiesofofthe theproperties the solid dosageform. solid dosage The The form. formulator formulator must balance must balance the the 2016202063
drug's unique properties drug's unique propertieswith thethe with properties of of properties each each excipient excipient in order in order to prepare to prepare a a
safe, efficacious safe, efficacious and easytotouse and easy soliddosage usesolid form. dosageform. Eltrombopag olamine Eltrombopag olamine presents presents the formulator the formulator with unique with unique concerns concerns when when
10 10 attemptingtotoformulate attempting formulatethis into into compound thiscompound a suitable a suitable oraloral solidsolid pharmaceutical pharmaceutical
dosage form, suitably a tablet, dosage form, suitably a suitablya acapsule, tablet,suitably witha adesirable capsule,with pharmacokinetic desirablepharmacokinetic on a particularly on profile, particularly profile, a commercial commercial scale. Such scale.Such concerns concerns include, include, but are are butnot not limited to; limited the tendency to; the ofthe tendency of compound thecompound to form to form insoluble metal metal insoluble complexes complexes when when contacted with contacted withexcipients excipientsthat a coordinating containa coordinating thatcontain metal, slowslow metal, dissolution dissolution of the of the
15 15 compoundfrom compound soliddosage fromsolid formsand dosageforms the tendency andthe the compound of the tendency of to under compound to go aa under go Maillard when reactionwhen Maillard reaction contacted withwith contacted excipients that that excipients contain contain reducing reducing sugars. sugars.
Significant ofthese realization of Significant realization these concerns havean an willhave concernswill adverse adverse effect the the on on effect in vivo in vivo
eltrombopag administrationofofeltrombopag administration olamine, olamine.
It would It desirabletotoprovide bedesirable would be eltrombopag provideeltrombopag olamine olamine in a solid in a solid oral oral 20 pharmaceutical 20 pharmaceutical dosage dosage form form on a a commercial oncommercial scale scale with with a desirable pharmacokinetic a desirablepharmacokinetic profile. profile.
presentinvention Thepresent The granulesandand directedtotogranules inventionis isdirected solid solid oral oral pharmaceutical pharmaccutical
dosagcforms dosage contain thatcontain formsthat eltrombopag eltrombopag olamine, olamine, suitably suitably the solid form isform dosagedosage the solid a is a tablet, suitably the tablet, suitably solid dosage the solid formisisaa capsule, dosage form capsule,suitably thesesolid suitablythese forms dosageforms soliddosage 25 25 are a commercial producedonona commercial are produced scale. scale.
SUMMARYOFOF SUMMARY THE INVENTION THEINVENTION
The relatestotogranules inventionrelates presentinvention Thepresent andand granules solid solid oral oral pharmaceutical pharmaccutical
30 dosage 30 dosage forms forms comprising comprising a therapeutically effective amount a therapeuticallyeffective eltrombopag of eltrombopag amount of olamine. The olamine. invention The alsoalso invention relates relates toprocess to a for for a process making making granules granules and solid solid and oral oral pharmaceutical dosage pharmaceutical forms comprising dosage forms olamine. eltrombopag olamine. comprising eltrombopag
-3-
In one aspect, the present invention relates to a solid oral pharmaceutical In one aspect, the present invention relates to a solid oral pharmaceutical
2016202063 17 Jul dosage formcomprising dosage form comprising thecompound the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5- 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-
dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'- dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-|[1,1'-
biphenyl]-3-carboxylic acid bis-(monoethanolamine) biphenyl]-3-carboxylic acid bis-(monoethanolamine) [eltrombopag
[eltrombopag olamine] olamine] and aand a
55 diluent component, diluent component, 2016202063
wherein thedosage wherein the dosage formform is formulated is formulated using ausing a diluent diluent or diluents or diluents that are that are
substantially freeofofcoordinating substantially free coordinating metals metals and are and that thatsubstantially are substantially free offree of reducing reducing
sugars, sugars, such such that that about about 5% or less 5% or less of of the thediluent diluentcomponent contains aa coordinating component contains coordinating
metal or metal or metals and/or aa reducing metals and/or sugar or reducing sugar or reducing sugars. reducing sugars.
- 3A - - 3A -
2016202063 17 Jul 2024
Another aspect Another aspect of of this this invention invention relates relates to granules to granules andoral and solid solid oral pharmaceuticaldosage pharmaceutical dosageforms, forms,suitably suitablytablets, tablets, suitably suitably capsules, capsules, comprising comprising
eltrombopag olamine that are formulated using diluents that are substantially free of eltrombopag olamine that are formulated using diluents that are substantially free of
reducing sugars, which as used herein and in the claims includes diluents that are reducing sugars, which as used herein and in the claims includes diluents that are
55 freeofofreducing free reducingsugars, sugars,and andthat thatare aresubstantially substantially free free of of coordinating coordinating metals, metals, which which
as usedherein hereinandand in in thethe claims includes diluents thatfree areoffree of coordinating 2016202063
as used claims includes diluents that are coordinating
metals. Such metals. Suchgranules granulesand andsolid solidoral oral pharmaceutical pharmaceuticaldosage dosageforms forms exhibit exhibit
improved properties. Such improved properties. Suchimproved improved properties properties help help to to ensure ensure safeandand safe effective effective
treatment. treatment.
10 10 Another aspect Another aspect of of this this invention invention relates relates to film to film coated coated pharmaceutical pharmaceutical
tablets comprising tablets eltrombopagolamine, comprising eltrombopag olamine,wherein wherein thethe filmcoat film coatcontains containsnono coordinating metals, coordinating metals, or or only only an an amount ofcoordinating amount of coordinatingmetal metalapproximately approximately equal equal
to or to or less lessthan than0.025 0.025parts partsofof Compound B.Such Compound B. Such tabletsexhibit tablets exhibitimproved improved properties. Such properties. improvedproperties Such improved propertieshelp helptotoensure ensuresafe safeand andeffective effective treatment. treatment. 15 15 Another aspect Another aspect of of this this invention invention relates relates to granules to granules andoral and solid solid oral pharmaceuticaldosage pharmaceutical dosageforms forms comprising comprising eltrombopag eltrombopag olamine olamine having having a particle a particle
size range in which X90 is in the range of 10 to 90 microns. Such tablets exhibit size range in which X90 is in the range of 10 to 90 microns. Such tablets exhibit
improved properties. Such improved properties. Suchimproved improved properties properties help help to to ensure ensure safeandand safe effective effective
treatment. treatment.
20 20 Another aspect Another aspect of of this this invention invention relates relates to granules to granules andoral and solid solid oral pharmaceuticaldosage pharmaceutical dosageforms forms containing containing eltrombopag eltrombopag olamine olamine comprising comprising a a high high percentage of percentage of disintegrant, disintegrant, suitably suitablyan anamount amount equal equal to to or or greater greaterthan than4%. 4%. Such Such
tablets exhibit tablets exhibitimproved improved properties. properties. Such improvedproperties Such improved propertieshelp helptotoensure ensuresafe safe and effectivetreatment. and effective treatment. 25 25 Another aspect Another aspect of of this this invention invention relates relates to a to a method method of treating of treating
thrombocytopenia, which thrombocytopenia, which method method comprises comprises administering administering to a to a subject subject in need in need
thereof a therapeutically effective amount of granules or a solid oral pharmaceutical thereof a therapeutically effective amount of granules or a solid oral pharmaceutical
dosage formofofthe dosage form the present present invention. invention. Another aspectof Another aspect of this this invention invention relates relatestotoa a method method of ofagonizing agonizing the the TPO TPO
30 receptor, 30 receptor, which which method method comprises comprises administering administering to a to a subject subject in need in need thereof thereof a a
therapeutically effective therapeutically effectiveamount of granules amount of granules or or aa solid solidoral oralpharmaceutical pharmaceutical dosage dosage
form of the present invention. form of the present invention.
--4-
04 Apr 2016
Also includedininthe Also included thepresent areare invention presentinvention methods methods of co-administering of co-administering
granules or a solid oral granules or a solid oral pharmaccutical pharmaceuticaldosage formform dosage of the the present of present invention invention with with further active further ingredients. active ingredients.
55 BRIEF DESCRIPTION THE DRAWINGS OF THE DESCRIPTION OF DRAWINGS 2016202063
Figure -- 1I Figure Figure IIdepicts Figure depictsthe comparison dissolutioncomparison thedissolution of tablets of tablets containing containing
eltrombopag eltrombopag andand a metal containing containing a metal diluent with with diluent tablets tablets containing containing eltrombopag eltrombopag and and a non-metal a containing non-metal containing diluent. diluent.
10 10
Figure -- 22 Figure Figure 22 depicts Figure ofAPI effect of theeffect depictsthe particlesize APIparticle dissolutionofof thedissolution sizeononthe from75mg ctrombopag from cltrombopag tablets. 75mgtablets.
15 15 DETAILED DESCRIPTION DETAILED OF THE DESCRIPTION OF INVENTION THE INVENTION
the term By the By "coordinating term"coordinating metal" and and metal" "coordinating "coordinating metals" metals" and derivatives and derivatives
thereof, as thereof, as used hereinisis meant used herein metalorora ametal meanta ametal containing metalcontaining excipient, excipient, suitably suitably a a diluent, or diluent, or metal containingtablet metal containing coatingmaterial, tabletcoating which material,which forms forms a complex, a complex, such such as as a chelatecomplex, 20 a chelate 20 thepresence complex,in inthe of eltrombopag presence of Examplesofofsuch olamine. Examples eltrombopag olamine. such include: metals include: metals
calcium, aluminum,calcium, aluminum, copper, copper, cobalt, cobalt, gold, gold, iron, iron, magnesium, magnesium, manganese manganese and and zinc. zinc.
By the By term"reducing the term "reducing sugar" sugar" as used as used herein hercin is meant is meant a sugar a sugar or sugar or sugar
25 25 containing suitablya adiluent, excipient,suitably containingexcipient, diluent,which with reactswith whichreacts eltrombopag eltrombopag olamine olamine to to formaa Maillard form product Maillardproduct when when admixed admixed together. together. Examples Examples of such reducing reducing of such sugars sugars include: include:
lactose, maltose, glucose, lactose, maltose, arabinoseandand glucose,arabinose fructose. fructose.
The term The Maillard termMaillard reaction is is reaction well well known known in art in the art and the and is utilized is utilized herein herein as as 30 30 to its to standard meaning. its standard meaning. Generally, thethe Generally, term term Maillard Maillard reaction reaction is used is used herein herein to to reactionofofa areducing thereaction meanthe mean reducing sugar, as as sugar, defined defined herein, a formulation, in ainformulation, herein, suitably suitably
granules ororsolid granules solid dosage forms, dosageforms, with with eltrombopag eltrombopag olamine olamine that produces that produces a pigment a pigment
-5-
04 Apr 2016
or pigments, suitably a brown or pigments, suitably a brownpigment. The pigments The pigments pigment. are referred are referred to herein to herein as as Maillard products. The production Maillard products. The of such of such production Maillard Maillard products products is an indication is an indication of of
instability. chemicalinstability. chemical
As used herein, the term "improved properties" As used herein, the term "improved and derivatives and derivatives properties" thereof, thereof,
55 contemplates several advantages to the contemplates several advantages pharmacokinetic to the profile pharmacokinetic inthe of theof profile vivo vivo release in release of Compound B from of Compound a formulation, B from suitably suitably a formulation, granules granules or a solid oral pharmaceutical solidpharmaceutical or a oral 2016202063
dosage form, dosage form,that aspectofofthe utilizesananaspect thatutilizes thepresent invention presentinvention when when compared compared to a to a formulation that formulation thatdoes doesnot notutilize utilizethat aspectofofthe that aspect thepresent suitablythethe invention,suitably presentinvention, produced formulationisisproduced formulation on on a commercial a commercial scale, scale, and vary and will vary depending will depending on the on the 10 particular 10 particular aspect aspect of the of the invention beingbeing invention utilized. utilized. Examples Examples of improved propertiesproperties of improved include: oralbioavailability, increasedoral include: increased formation reducedformation bioavailability, reduced of insoluble of insoluble metal metal
complexes, improved complexes, chemical chemical improved stability, stability, a consistent a consistent pharmacokinetic profile profile pharmacokinetic and a and a consistent dissolution consistent rate. dissolution rate. As usedherein, Asused theterm herein,the or or "drug" term"drug" "active "active ingredient" and and ingredient" derivatives derivatives
15 15 thereof, means thereof, Compound B Bororeltrombopag means Compound olamine. eltrombopagolamine. By the term By the "commercial term"commercial scale" scale" and derivatives and derivatives thereof, thereof, as used hercinherein as used is is meant, preparation meant, preparationofof a a batchscale batch scale greaterthan greater than about about 20 of 20 kg kggranulation of granulation mix, mix, suitably greater than suitably greater kg,suitably 50kg, than 50 suitablygreater or or than7575kgkg greaterthan a batch a batch size size suitableto to suitable
least about prepare atat least prepare tablets,suitably 50,000tablets, about 50,000 75,000tablets, least 75,000 suitablyatatleast suitably atat tablets, suitably 20 20 least tablets. 100,000tablets. least 100,000 When indicating When indicating that thethe that diluentsforfor diluents use use herein andand herein in the in the claims are are claims substantially of coordinating free of substantially free coordinatingmetals and/or metalsand/or that that are substantially aresubstantially freeof of free
reducing is contemplated sugars,itit is reducingsugars, contemplatedthat minor thatminor amounts, amounts, for example: about about for example: 5% or 5% or less, of the less, of diluent component the diluent could component could contain contain a coordinating a coordinating metal metal or metals and/orand/or or metals a a 25 25 reducing sugarororreducing reducingsugar reducing sugars. sugars. In this In this aspect aspect of the of the invention, invention, it is it is believed believed that that
amounts minoramounts very minor very of coordinating of coordinating metals and/orand/or metals reducing sugars sugars reducing can be can be incorporated thediluent intothe incorporatedinto component diluentcomponent without without adversely adversely effecting tablettablet effecting performance. performance.
Theterm The "effectiveamount" term"effective and and amount" derivatives derivatives thereof, meansmeans thereof, that amount that amount of a of a 30 drugdrug 30 or active or active ingredient ingredient that will that will elicit the the elicit biological biological or medical or medical response response of a of a tissue, system, tissue, animalororhuman system, animal human is is thatthat being being sought, for for sought, instance, by aby instance, a researcher researcher or or term Furthermore,thetheterm clinician. Furthermore, clinician. "therapeutically "therapeutically effective effective amount" means means amount" any any
-6-6
2016202063 04 Apr 2016
amount which, as as amount which, compared to a to compared corresponding who haswho subjectsubject a corresponding has not received not received such such amount, results in improved treatment, amount, results in improved healing, healing, treatment, prevention, prevention, or amelioration or amclioration of a of a disease, disorder, or disease, disorder, or side or aa decrease effect, or side effect, in the decrease in rate of the rate advancement of of of advancement a disease a disease
or disorder. The term or disorder. The also term includes alsoincludes within its its within scope scope amounts amounts effective effective to enhance to enhance
5 5 normal function. physiologicalfunction. normalphysiological As Asused usedherein, herein,the term"formulation" theterm and and "formulation" derivatives derivatives thereof, thereof, unless unless 2016202063
otherwise defined refers otherwise defined referstotogranules and/or granulesand/or solid solid oral oral pharmaceutical pharmaccutical dosage dosage forms forms
of the of invention that the invention eltrombopag containeltrombopag that contain olamine. olamine.
By By the theterm "co-administering" term"co-administering" and and derivatives derivatives thereof thereof as used hereinherein as used is is 10 10 meant meanteither simultaneous eithersimultaneous administration administration or any or any manner manner of separate of separate sequential sequential
administration and/or granulesand/or administrationofofgranules a solid pharmaceutical oralpharmaceutical a solidoral dosage dosage form of theof form the present invention present furtheractive anda afurther inventionand known ingredients,known ingredientor oringredients, activeingredient to treat to treat
thrombocytopenia, including chemotherapy-induced thrombocytopenia, including chemotherapy-induced thrombocytopenia bone andbone thrombocytopeniaand marrow marrowtransplantation andand transplantation other other conditions with with conditions depressed depressed platelet platelet production. production. The The
15 15 term term further active ingredient further active ingredients,asasused ingredientororingredients, herein,includes usedherein, anyany includes compound compound
or therapeutic agent or therapeutic known agentknown to or to or that that demonstrates demonstrates advantageous advantageous properties properties when when withTPOTPO administeredwith administered a TPO or aorTPO mimetic, mimetic. Preferably, Preferably, if the administration if the administration is not is not compounds simultaneous,thethecompounds simultaneous, are administered are administered in a close in a close time proximity time proximity to each to each other, Furthermore, other. if if matter doesnotnotmatter Furthermore,it itdoes thethecompounds compounds are administered in the in are administered the 20 20 dosage samedosage same form, form, e.g.oneone e.g. compound may be may compound administered topicallytopically be administered and and another another compound be be may compoundmay administered orally. administeredorally. Examplesof of Examples a further activeingredient a furtheractive or or ingredient ingredients ingredients useuse for for in combination in combination
with the presently with the formulations inventedformulations presently invented include but but include not not are are limited limited to: to: chemoprotective or chemoprotective mycloprotective agents or mycloprotective G-CSF, BB10010 asG-CSF, such as agents such (Clemonsetet BB10010 (Clemons
25 25 Breast Cancer al., Breast al., Cancer Res. Treatment, Res.Treatment, 1999, 57, 57, 1999, 127), 127), amifostine amifostine (Ethyol) (Ethyol) (Fetscher (Fetscher et et al., Opinion ininHemat., Current Opinion al., Current 2000, Hemat.,2000, 7, 255-60), SCF,SCF, 7, 255-60), IL-11, MCP-4,MCP-4, IL-11, IL-I IL-1-beta, -beta, AcSDKP AcSDKP (Gaudron (Gaudron et al., Stem et al., Cells, 1999, StemCells, 17, 100-6), 1999, 17, TGF-b, MIP-la TNF-a, TGF-b, 100-6),TNF-a, MIP-1a
al., Bone (Eggeretet al., (Egger Marrow Bone Marrow Transpl., Transpl., 1998, 1998, 22 (Suppl. 22 (Suppl. 2), 34-35), 2), 34-35), and and other other having identifiedasashaving moleculesidentified molecules anti-apoptotic, anti-apoptotic, survival or or survival proliferative proliferative properties. properties.
30 30 By the By "granules"andand term"granules" the term derivatives derivatives thereof, thereof, as used as used herein herein refers refers to to particlesthat formulatedparticles formulated comprise thatcomprise eltrombopag eltrombopag olamine, olamine, diluents diluents that that are are substantially free substantially coordinatingmetals of coordinating free of and/or metalsand/or thatarearesubstantially that freeof of substantiallyfree
-7-
04 Apr 2016
reducing sugars, and suitably also alsobinders and/or and/or binders lubricants lubricants and/or and/or disintegrants such such disintegrants reducing sugars, and suitably that the particles are are suitable for utilization suitable for preparing solid utilizationininpreparing oralpharmaceutical solid oral pharmaccutical that the particles dosage forms. It It dosage forms. isisalso alsopossible administer possibletotoadminister thethe granules granules directly to to directly a subject a subject in in need thereofasasaamedicament. need thereof medicament. However, However, it is anticipated it is anticipated that the the granules thatgranules are are most most 5 appropriately utilized 5 appropriately utilized the preparation in preparation in the of solid oral oral of solid pharmaceutical pharmaceutical forms asforms dosage dosage as above. indicated above. indicated 2016202063
Bythe By the term "solidoral term"solid pharmaceutical oralpharmaceutical dosage form"form" dosage and "solid dosagedosage and "solid form" form"and andderivatives derivativesthereof, asas thereof, used used herein herein refers to to refers a final pharmaceutical a finalpharmaceutical that comprises preparation that preparation eltrombopag compriseseltrombopag olamine, olamine, such tablets, such tablets, capsules, capsules, pellets, pellets,
10 lozenges 10 lozenges and powders and powders (including (including coated versions of any ofof coated versions such of such preparations) anypreparations) that that are suitable are suitable for in vivo for in administration. vivo administration.
Suitably, the Suitably, andsolid granulesand the granules oralpharmaccutical solidoral pharmaceuticaldosage of theof the formsforms dosage present invention present comprise inventioncomprise eltrombopag eltrombopag olamine, olamine, a diluent known known (also (also a diluent as orfiller as filler or bulkingagent), bulking andsuitably agent),and binder alsoa abinder suitablyalso and/or and/or a lubricant a lubricant and/or and/or a disintegrant. a disintegrant.
Those 15 Those 15 skilled skilled in art in the art will the will recognize that that recognize a given a given material material may provide may provide one one or more or more functions inin the functions the tablet formulation,although tablet formulation, materialis isusually althoughthethematerial usuallyincluded for for included a a function.TheThe primaryfunction. primary percentages percentages of diluent, of diluent, binder, binder, lubricant lubricant and disintegrant and disintegrant
provided andin inthetheclaims hereinand providedherein by by areare claims weight weight of the of the tablet. tablet.
providebulk, Diluents provide Diluents example, bulk,forforexample, in order in order to make to make the tablet the tablet a practical a practical
20 sizesize 20 for for processing. processing. Diluents Diluents mayaidalso may also aid processing, processing, for example, for example, by providing by providing
physical improvedphysical improved properties properties such such as flow, as flow, compressibility, compressibility, and tablet and tablet hardness. hardness.
Because therelatively Becauseofofthe highpercentage relativelyhigh of of percentage diluent andand diluent the the amount amount of direct of direct contact contact
between between the thethe diluentandand thediluent active active compound compound the typical in theintypical pharmaceutical pharmaceutical
theinteraction formulation,the formulation, diluentwith thediluent interaction ofofthe activecompound theactive withthe of particular is ofisparticular compound 25 25 the formulator. concerntotothe concern Examples formulator.Examples of diluents of diluents suitable suitable for general for general use include: use include:
water-soluble andwater-insoluble fillers and water-solublefillers fillers, such water-insolublefillers, calcium suchasascalcium phosphate phosphate (e.g., (e.g., di di and tri and tri basic, basic, hydrated or anhydrous). hydrated or anhydrous),calcium calcium sulfate, sulfate, calcium calcium carbonate, carbonate,
magnesium magnesium carbonate, carbonate, kaolin, kaolin, spray drieddried spray or anhydrous or anhydrous lactose, lactose, cellulose (e.g., (e.g., cellulose microcrystallinecellulose, microcrystalline powdered cellulose, powdcred cellulose), cellulose), pregelatinized pregelatinized starch, starch, starch, starch,
lactitol, 30 lactitol, 30 mannitol, mannitol, sorbitol, sorbitol, maltodextrin, maltodextrin, powdered sugar, sugar, powdered compressible compressible sugar, sugar, sucrose, dextrose, sucrose, andinositol. dextrose,and The inositol. The diluents diluents thatdo do that notnot contain contain coordinating coordinating metals metals
and diluents and are non-reducing that are diluents that non-reducingsugars areare sugars suitable forfor suitable tablets thethe of of tablets current current
- 8-
04 Apr 2016
invention. invention. Suitable diluentsforforuse Suitablediluents include inventioninclude thisinvention useininthis microcrystalline microcrystalline
cellulose, powdered cellulose, cellulose, powdered cellulose,pregelatinized starch, pregelatinized starch, starch, lactitol, starch, mannitol, lactitol,mannitol, sorbitol, and maltodextrin. Unsuitable sorbitol, and maltodextrin. diluents Unsuitable include include diluents calcium calcium phosphate (e.g., (e.g., phosphate di di and and tri basic, hydrated tri basic, hydrated or or anhydrous), calcium anhydrous),calcium sulfate, sulfate, calcium calcium carbonate, carbonate,
55 magnesium magnesium carbonate, carbonate, kaolin, kaolin, drieddried sprayspray and and or anhydrous or anhydrous lactose. lactose. In one In one embodiment embodiment of the present of the invention, present the the invention, diluent diluent is composed is composed bothorofboth orone of oneof of 2016202063
Mannitoland Mannitol microcrystalline andmicrocrystalline cellulose. cellulose.
The granulesandand Thegranules solidoral solid pharmaceutical oralpharmaceutical dosage dosage of theof forms forms the present present
invention invention typically typicallycomprise comprise from from about 25% 25% about to about to about 89%, of one of 89%, one or or more more diluents. diluents.
10 10 Oneaspect One thepresent aspectofofthe invention presentinvention comprises comprises granules granules wherein wherein the granules the granules
are are formulated formulatedusing diluentsthat a diluentorordiluents usinga diluent aresubstantially thatare freeofofcoordinating substantiallyfree coordinating
and/orthat metals and/or metals aresubstantially thatare free ofofreducing substantiallyfree sugars. reducingsugars. One Oneaspect aspectofofthe thepresent invention presentinvention comprises comprises solid oraloral solid pharmaceutical pharmaceutical
dosageforms dosage the the wherein formswherein solid solid dosage formsforms dosage are formulated using ausing are formulated a diluent diluent or or 15 15 diluents that diluents are substantially that are substantially free of coordinating free of coordinating metals and/or metalsand/or thatareare that
of reducing free of substantially free substantially sugars. reducingsugars. aspectofofthe Oneaspect One invention presentinvention thepresent comprises comprises pharmaceutical pharmaccutical tablets, tablets,
wherein thetablets whereinthe areformulated tabletsare using formulatedusing a diluent or or a diluent diluents diluents that areare that substantially substantially
free of coordinating free of metalsand/or coordinating metals thatarearesubstantially and/orthat freeofof substantiallyfree reducing reducing sugars. sugars.
20 20 Oneaspect One aspectofofthe thepresent presentinvention invention comprises comprises pharmaceutical pharmaceutical capsules, capsules,
capsulesareareformulated thecapsules whereinthe wherein formulated using using a diluent a diluent or diluents thatthat or diluents are are substantially substantially
free of coordinating free of and/or metalsand/or coordinating metals thatarearesubstantially that freeofofreducing substantiallyfree reducing sugars. sugars.
Bindersimpart Binders cohesive impartcohesive properties properties to the to the powdered powdered material, material. Examples Examples of of binders suitable binders use in for use suitable for in the the present include:starch inventioninclude: present invention paste, (e.g., paste, starch(c.g.,
25 25 pregelatinized, gelatin,sugars mucilage),gelatin, pregelatinized, mucilage), sucrose,glucose, (e.g., sucrose, sugars(e.g., molasses, dextrose,molasses, glucose,dextrose,
lactose, dextrin, lactose, sorbitol),polymethacrylates, xylitol, sorbitol), dextrin, xylitol, polymethacrylates, natural andsynthetic natural and gums syntheticgums (e.g., acacia, alginic (e.g., acacia, alginic acids acids and and salts salts thereof thereof such such as sodium alginate, as sodium alginate,gum tragacanth, gum tragacanth, Irish moss Irish moss extract, gum, panwargum, extract, panwar ghatti ghatti gum, guarguar gum, zein),zein), gum, gum, cellulose cellulose derivatives derivatives
as carboxymethyl
[such as
[such carboxymethyl cellulose and and cellulose salts salts thereof, thereof, methyl methyl cellulose (MC),(MC), cellulose
hydroxypropyl 30 hydroxypropyl 30 methyl methyl cellulose cellulose (HPMC), (HPMC), hydroxypropyl hydroxypropyl cellulose cellulose (HPC), (HPC),
cellulose hydroxyethylcellulose hydroxycthyl (HEC) ethylethyl and and (HEC) cellulose cellulose (EC)], (EC)], polyvinylpyrrolidone, polyvinylpyrrolidone,
Veegum, Veegum, larch larch arabogalactan, arabogalactan, polyethylene polyethylene glycol, glycol, waxes, water, water, waxes, alcohol, alcohol,
-9-
04 Apr 2016
magnesium aluminum silicate, magnesium aluminum silicate, and bentonites. In one In and bentonites. one embodiment embodiment of the of the present present invention, the binder invention, the comprises bindercomprises polyvinylpyrrolidone polyvinylpyrrolidone (PVP). (PVP).
The granulesandand Thegranules solidoral solid pharmaceutical oralpharmaceutical dosage dosage of the of forms forms the present present
invention comprise typicallycomprise invention typically up up to to about about 8% binder. 8% binder. The formulations suitablysuitably The formulations 5 5 compriseupuptotoabout comprise 5%,5%, about suitably suitably up to to about up about 2% binder. 2% binder.
aregenerally Lubricantsare Lubricants to to used generallyused enhance enhance processing, processing, for example, for example, to prevent to prevent 2016202063
2016202063
adhesionofofthe adhesion formulation theformulation material material to manufacturing to manufacturing equipment, equipment, reduce reduce friction, improve interparticle friction, interparticle rate of improve rate of flow formulation,and/or the formulation, flow ofofthe ejection assistejection and/orassist the formulations of the of fromthethe formulations from manufacturing manufacturing equipment. equipment. Examples Examples of lubricants of lubricants
10 10 suitable for suitable use in for use the present in the present invention include:talc, inventioninclude: (e.g., magnesium stearates (e.g., talc, stearates magnesium
stearate, calcium stearate, stearate, zinc calcium stearate, palmitostearate) stearic stearate, palmitostearate), zinc stearate, acid, hydrogenated stearic acid, hydrogenated
oils, glyceryl vegetableoils, vegetable polyethylene behanate,polycthylene glyceryl behanate, glycol, glycol, ethylene ethylene oxide oxide polymers polymers
CARBOWAXes), liquid liquid (e.g., CARBOWAXes), (c.g., paraffin, sodiumsodium paraffin, lauryl sulfate, lauryl sulfate, magnesium magnesium lauryl lauryl sulfate, sodium sulfate, sodium oleate, sodium oleate, sodium stearyl stearyl fumarate, fumarate, DL-leucine, DL-leucine, and silica and silica derivatives derivatives
15 colloidal (e.g.,colloidal 15 (c.g., silicon silicon dioxide, dioxide, colloidal colloidal silica, pyrogenic silica,pyrogenic silica, andand silica, hydrated hydrated
silicoaluminate). sodiumsilicoaluminate). sodium In one In one embodiment of the of embodiment the present present invention, invention, the lubricant the lubricant
comprises magnesium comprises stearate. magnesiumstearate. The granulesandandsolid Thegranules solidoral pharmaceutical oralpharmaceutical dosage dosage of the of forms forms the present present
comprise typicallycomprise invention typically invention up up to to about about 2% lubricant. 2% lubricant. The formulations The formulations suitably suitably
20 20 compriseupuptotoabout comprise about 1.5%, 1.5%, suitably suitably up to to about up about 1% lubricant. 1% lubricant.
areemployed Disintegrantsare Disintegrants employedto facilitate breakup to facilitatebreakup or disintegration or disintegration of the of the
afteradministration. formulationafter formulation Examples administration.Examples of disintegrants of disintegrants suitable suitable for inusethein for use the present include:starches, inventioninclude: present invention gums, celluloses,gums, starches,celluloses, crosslinked crosslinked polymers, polymers, and and effervescentagents, effervescent cornstarch, suchasascorn agents,such starch,potato pregelatinized starch,pregelatinized potatostarch, starch, starch,
25 25 modifiedcorn modified starch,croscarmellose cornstarch, croscarmellose sodium, sodium, crospovidone, sodium sodium crospovidone, starch starch Veegum glycolate, Vecgum glycolate, HV, HV, methyl methyl cellulose, cellulose, microcrystalline microcrystalline cellulose, cellulose, cellulose, cellulose,
modifiedcellulose modified gum cellulosegum Ac-Di-Sol (e.g.,Ac-Di-Sol (e.g., R), R), agar, agar, bentonite, bentonite, montmorillonite montmorillonite clay, clay, natural sponge,cation natural sponge, exchange cationexchange resins, ionion resins, exchange exchange resins resins (e.g., (e.g., polyacrin polyacrin
potassium), acidand alginicacid potassium),alginic guar alginates,guar andalginates, gum, gum, citrus citrus pulp, pulp,
30 30 carboxymethylcellulose carboxymethylcellulose and and salts salts thereof suchsuch thereof as sodium lauryllauryl as sodium sulfate, sulfate, magnesium magnesium
aluminum aluminum silicate, hydrous silicate,hydrous aluminum aluminum silicate, silicate, sodium sodium bicarbonate bicarbonate in admixture in admixture
- 10-
04 Apr 2016
with an acidulant such with an acidulant acidororcitric tartaricacid suchasastartaric embodiment oneembodiment acid. InIn one citric acid. of the of the
present invention, present disintegrantisis sodium thedisintegrant invention,the starch sodiumstarch glycolate. glycolate.
The granules and The granules and solidoral solid pharmaceutical oralpharmaceutical dosage dosage of the of forms forms the present present
invention typicallycomprise invention typically comprisean an amount amount 4% to 4% from from to 12% about about 12% disintegrant. disintegrant. The The
5 5 formulations suitably formulations comprise suitablycomprise from from about 6% to6% about to about about 10%, suitably 10%, suitably from from about about 7%toto9%9% 7% disintegrant. disintegrant. 2016202063
The solidoral Thesolid pharmaceutical oral pharmaccutical dosage dosage forms, forms, suitably suitably tablets, tablets, suitably suitably
capsules, of the present invention will typically I gram, sizedupuptoto1 gram, capsules, of the present invention will typically bebesized e.g., from e.g.,from about 0.01 about gram 0.01 gram to to about 0.80.8 about gram. solid solid TheseThese gram. dosage dosage forms typically forms typically comprise comprise
10 from 10 from about about 5 mg 5 mg to about 900900 to about of of mg mg eltrombopag eltrombopag olamine perper olamine dosage dosage form. form. In In suitable embodiments, suitable embodiments, thethe solid solid dosage dosage forms forms comprise comprise from5 about from about 5 to200 to about about 200 mg eltrombopag mgeltrombopag olamine olaminc (e.g., (c.g., in an an about in about 100-800 100-800 mg dosage mg dosage form). form). Tablet Tablet formulationsofofthe formulations theinvention havehave inventionmaymay a variety a variety of shapes, of shapes, including including diamond, diamond,
modifiedcapsule, modified modified capsule,modified oval, and and oval, hexagonal, hexagonal, and may may optionally andoptionally have have a tilt. a tilt. 15 15
Tablets Tablets
choiceofofparticular Thechoice The typesandand particulartypes amounts amounts of excipients, of excipients, and tabletting and tabletting
technique employed techniqueemployed depends depends on the the further onfurther properties properties of eltrombopag olamine olamine of eltrombopag and and 20 the the 20 excipients, excipients, e.g., e.g., compressibility, compressibility, flowability, flowability, particle particle size, size, compatibility, compatibility, and and density. The density. may tabletsmay Thetablets be be prepared prepared according according to methods to methods known known in in the the art, art, includingdirect including compression, directcompression, drydry granulation, granulation, fluid bedbed fluid granulation, granulation, and and wet wet granulation, typeofofexcipients thetype andthe granulation, and used excipientsused will will vary vary accordingly. accordingly. It has It has foundfound beenbeen
that wet that granulationisisparticularly wet granulation particularlysuitable providinghigh for providing suitable for strength,lowlow highstrength, breakage 25 breakage 25 tablets tablets comprising comprising relatively relatively high concentrations high concentrations of eltrombopag of eltrombopag olamine olamine 40% % about 40 (e.g., about (e.g., oror on on more), more), a scale a scale suitable forfor suitable commercial commercial production. production. Suitable Suitable
wet granulated wet tabletsofofthe granulatedtablets theinvention comprise inventioncomprise granules granules comprising comprising eltrombopag eltrombopag
olamine or or andoneone olamineand more more of fillers, of fillers, binders andand binders disintegrants, disintegrants, wherein wherein the granules the granules
are mixed are additional withadditional mixedwith filler, binder,disintegrant filler,binder, lubricanttotoform and/orlubricant disintegrantand/or form a a 30 30 compression compression mixture thatthat mixture is compressed is compressed to form to form tablets. tablets.
Includedininthe Included thepresent pharmaceutical inventionarearepharmaceutical presentinvention compositions compositions in tablet in tablet
form, suitably form, suitably prepared preparedonona commercial a commercial scale, scale, thatthat comprise comprise eltrombopag olamine,olamine, eltrombopag
2016202063 17 Jul 2024
wherein the tablet is made by a wet granulation process using a diluent or diluents wherein the tablet is made by a wet granulation process using a diluent or diluents
that are substantially free of coordinating metals and/or that are substantially free of that are substantially free of coordinating metals and/or that are substantially free of
reducing sugars. reducing sugars. Also Alsoincluded includedininthe the present present invention invention are are such such pharmaceutical pharmaceutical compositions that contain a film coat, wherein the film coat contains no compositions that contain a film coat, wherein the film coat contains no
55 coordinating coordinating metals, metals, or or only only anan amount amount of coordinating of coordinating metal metal approximately approximately equalequal
to or or less lessthan than0.025 0.025parts partsofof Compound B. 2016202063
to Compound B.
Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe tablet tablet isismade madeby by a wet a wet granulation granulation
process, suitably on a commercial scale, using a diluent or diluents that are process, suitably on a commercial scale, using a diluent or diluents that are
10 substantially 10 substantially free free ofof coordinating coordinating metals metals and/or and/or thatare that aresubstantially substantially free free of of
reducing sugars, reducing sugars, and and the the eltrombopag olamine eltrombopag olamine particleshave particles havea aparticle particle size size range range
in which in X90isis greater which X90 greater than than 10 10 micron micronbut butless less than than 90 micron. 90 micron.
Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe tablet tablet isismade madeby by a wet a wet granulation granulation
15 process, 15 process, suitably suitably on on a commercial a commercial scale, scale, using using a diluent a diluent or or diluentsthat diluents thatare are substantially free of coordinating metals and/or that are substantially free of substantially free of coordinating metals and/or that are substantially free of
reducing sugars, reducing sugars, and and the the eltrombopag olamine eltrombopag olamine particleshave particles havea aparticle particle size size range range
in which X90 is greater than 10 micron but less than 90 micron, suitably greater in which X90 is greater than 10 micron but less than 90 micron, suitably greater
than 20 than micronbut 20 micron butless less than than 50 micron. 50 micron.
20 20 Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe tablet tablet isismade madeby by a wet a wet granulation granulation
process, suitably on a commercial scale, using a diluent or diluents that are process, suitably on a commercial scale, using a diluent or diluents that are
substantially free of coordinating metals and/or that are substantially free of substantially free of coordinating metals and/or that are substantially free of
reducing sugars, reducing sugars, and and the the eltrombopag olamine eltrombopag olamine particleshave particles havea aparticle particle size size range range
25 in which 25 in which X50 X50 is greater is greater thanthan 5 micron 5 micron but less but less thanthan 50 micron, 50 micron, suitably suitably greater greater
than 55 micron than but less micron but less than than 20 20 micron. micron.
In one embodiment of the present invention, the tablets of the present In one embodiment of the present invention, the tablets of the present
invention comprise: invention comprise: 30 30 (i) (i) from about from about2% 2%totoabout about65% 65% eltrombopag eltrombopag olamine; olamine;
(ii) (ii) from from about about 25% 25% to about to about 89% 89% of of diluent; diluent;
- 12 -
04 Apr 2016
(iii) up to about 8% binder, suitably (iii) up to about 8% binder, up toup suitably to about about 5%, suitably 5%, suitably up to up to about about 4%; 4%; (iv) (iv) up to about 2% lubricant, suitably up to about 2% lubricant, to to suitablyup up about about 1.5%, 1.5%, suitably suitably up up to to 1%; and about 1%; about and 5 5 (v) (v) from4%4%to toabout from 12%12% about disintegrant, disintegrant, suitably 6% to6% suitably 10%, 10%, suitably to suitably 7%toto 9%. from 7% from 9%. 2016202063
Suitable wet wetgranulated granulatedtablets by by comprise, tabletscomprise, weight weight of tablet, of the aboutabout fromfrom the tablet, Suitable 10% to about 95% 10% to about of eltrombopag 95% olamine of eltrombopag active active olamine intragranules and fromand intragranules from about 5% about 5% to to about 90%ofof about 90% excipients; externalexcipients; external wherein the the wherein eltrombopag eltrombopag olamine active active olamine 10 10 intragranules weight comprise,bybyweight intragranules comprise, of the of the intragranules: intragranules:
(i) (i) from about 2% from about about 88% to about 2% to 88% eltrombopag olamine; eltrombopagolamine; (ii) (ii) from about10%10% fromabout to about 96% 96% to about diluent; diluent;
(iii) (iii) from about 2% from about 2% to about 5% to about binder; and 5% binder; and
from0%0% optionallyfrom (iv) optionally (iv) totoabout disintegrant; about4%4%disintegrant; 15 15 and wherein and excipients externalexcipients whereinthetheexternal comprise, comprise, by weight by weight of the the tablet: oftablet:
(i) (i) from 70%70% about from0%0%to toabout diluent; diluent;
(ii) (ii) from about from 0.25% about0.25% to about 2%, 2%, to about suitably about about from from suitably 0.25% to aboutto 0.25% about 1.25%lubricant; 1.25% and lubricant;and (iii) (iii) from 10%10% about from 4%4%totoabout disintegrant. disintegrant.
20 20 In the In the foregoing embodiments, foregoing embodiments, the the diluent diluent is suitably is suitably a combination a combination of of mannitoland mannitol andmicrocrystalline microcrystalline cellulose, cellulose, thethe non-reducing non-reducing sugarsugar is suitably is suitably mannitol, mannitol,
the is suitably binder is the binder polyvinylpyrolidone,thethe suitably polyvinylpyrolidone, lubricant is is lubricant suitably magnesium suitablymagnesium stearate, and stearate, and the is suitably disintegrant is the disintegrant suitably sodium starchglycolate. sodiumstarch thethe Suitably, glycolate.Suitably, 25 25 intragranule mixture of filler isisaamixture intragranule filler of mannitol mannitol and microcrystallinecellulose andmicrocrystalline the the andand cellulose external filler is microcrystalline cellulose, external filler is microcrystalline cellulose.
In one In embodiment one embodiment of the of the current current invention, invention, tablets are are tablets coated with with coated a a film film coat formed coat an an from formedfrom aqueous coat coat film film aqueous composition. composition. film coatfilm AqueousAqueous coat compositions suitableforforuseusein inthethepresent compositionssuitable invention presentinvention comprise comprise a film-forming a film-forming
30 30 polymer, a vehicle,andand waterasasa vehicle, polymer,water optionally oneone optionally or more or more adjuvants adjuvants such as areas such are known known in the film-coating in the film-coating art. When art. When thethe film film coat coat contains contains a coordinating a coordinating metal, metal, as as used used
13 -
04 Apr 2016
herein, herein, the amountofof the amount coordinating coordinating metal metal is approximately to or to equalequal is approximately or than less 0.025 0.025 less than ofCompound parts of parts B. Compound B.
The film-forming The film-forming polymer polymer is selected is selected to form to form coatings coatings with mechanical with mechanical
properties (e.g., mechanical properties (e.g., strength,flexibility) mechanical strength, to meet suitable to flexibility) suitable performance meetperformance 5 5 requirements, such such requirements, as those as those required by the by required the intended intended use environment use environment (e.g., (e.g., dissolution profile in gastrointestinal fluids), and/or use (e.g. solution viscosity). dissolution profile in gastrointestinal fluids), and/or use (e.g. solution viscosity). 2016202063
Examplesof of Examples film-forming suitablefilm-forming suitable polymers polymers include include cellulosic cellulosic polymers polymers (e.g., (e.g., celluloseethers cellulose suchas as etherssuch HPMC, HPC, HPMC, MC,EC, HPC, MC, HEC, EC,HEC, CAP, CAP, sodium sodium ethyl ethyl cellulose cellulose
sulfate, carboxymethyl sulfate, cellulose carboxymethyl cellulose thethe andand like); like); polyvinylpyrolidone; zein;zein; polyvinyipyrolidone; and and 10 10 acrylic polymers(e.g., acrylic polymers methacrylicacid/methacrylic (e.g., methacrylic acidacid acid/methacrylic ester ester copolymers copolymers such such as as methacrylic acid/methylmethacrylate methacrylicacid/methylmethacrylate copolymers and theand copolymers the Cellulosic like). polymerspolymers like). Cellulosic the present preferred inin the are preferred are invention,especially present invention, ethersand cellulosicethers especiallycellulosic more andmore especially HPMC especially HPC. andHPC. HPMC and TheThe polymers are are polymers typically either aqueous providedinin either typicallyprovided aqueous
or organic solvent or organic solutionsor or basedsolutions solventbased aqueous aqucous dispersions. dispersions. However, However, the polymers the polymers
15 15 maybebeprovided may provided drydry in in form, form, alone alone or in a powdery or ainpowdery mixture mixture with other other components with components (e.g., colorant), which and/or colorant), plasticizerand/or (e.g., aaplasticizer is made which is intoa asolution made into dispersionbyby solutionorordispersion the user the user by admixing by admixing with thethe with aqueous aqueous vehicle. vehicle.
Theaqueous The aqueous film film coat coat composition composition further further comprises comprises water water as as a vehicle a vehicle for for the other the components, other components, to to facilitatetheir facilitate thetablet deliverytotothe theirdelivery tablet surface. vehicle Thevehicle surface. The 20 may may 20 optionally optionally further further comprise comprise one or one or more more water soluble soluble solvents, watersolvents, e.g., e.g., alcohols alcohols (e.g., methanol, (e.g., methanol, isopropanol, andand propanol) isopropanol,propanol) ketones ketones (e.g., (e.g., acetone). acetone). The skilled The skilled
artisan can artisan select appropriate can select components vehiclecomponents appropriate vehicle to provide good good to provide interaction interaction
betweenthethefilm-forming between film-forming polymer polymer and the the vehicle andvehicle to ensure to ensure good film film properties. goodproperties. In general, In polymer- -- vehicle general, polymer is designed interaction is vehicle interaction to yield designed to maximum yield maximum polymer polymer
25 chainchain 25 extension extension to produce to produce films having films having the greatest the greatest strength strength cohesivecohesive and thus and thus properties.TheThe mechanicalproperties. mechanical components components are also also selected areselected to provide to provide good deposition good deposition
of the film-forming of the polymer film-formingpolymer the the ontoonto tablet tablet surface, suchsuch surface. thatthat a coherent a coherent and and filmisis achieved. adherent film adherent achieved. The aqueous The aqueous film film coating coating composition composition may optionally may optionally comprise comprise one or more one or more
30 adjuvants 30 in the in knownknown adjuvants art, art, as thesuch such as plasticizers, plasticizers, colorants, colorants, detackifiers, detackifiers, secondary secondary
polymers, film-formingpolymers, film-forming flow flow aids, aids, surfactants surfactants (e.g.,to to (e.g., assist spreading), assistspreading), andpolydextrose. maltodextrin,and maltodextrin, polydextrose.
- 14
04 Apr 2016
Plasticizers provide Plasticizers flexibility to provide flexibility film, which the Film, to the which may reduce mayreduce film film cracking cracking
and improve adhesion to the tablet. and improve adhesion to the Suitable tablet. Suitable willwill plasticizers plasticizers generally havehave generally a high a high
degree of compatibility degree of compatibilitywith thethe with film-forming film-forming polymer polymer and sufficient and sufficient permanence permanence
such that such that the the coating coatingproperties generallystable. aregenerally propertiesare Examples stable.Examples of suitable of suitable
55 plasticizers include include plasticizers glycerin, glycerin, propylene propylene glycol, glycol, polyethylene glycolsglycols polyethylene (e.g., molecular (e.g., molecular
weight to to from200200 weightfrom 20,000, 20,000, including including Union Union Carbide's Carbide's PEG PEG 400, 400, 4000, 4000, 6000, 6000, 8000, 8000, 2016202063
and 20,000), and triacetate(aka glycerintriacetate 20,000),glycerin monoglyceride, acetylated monoglyceride, triacetin), acetylated (akatriacetin), citrate citrate
esters (e.g., triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl esters (e.g., triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl
citrate), phthalate citrate), (e.g.,diethyl esters (e.g., phthalate esters mineral oil phthalate),mineral diethylphthalate), and hydrogenated oiland hydrogenated
10 glucose 10 glucose syrup. syrup. one embodiment In oneInembodiment of the present present invention, of the invention. the plasticizer is chosen is the plasticizer chosen from polyethylene frompolycthylene glycols, glycols, triacetin, propylene triacetin,propylene glycol, glycol, glycerin, and and glycerin, mixtures mixtures
thereof. thereof.
The aqueous Theaqueous film film coat coat composition composition suitably suitably comprises moreor one or one comprises more colorants. enhancing additiontotoenhancing colorants. InInaddition esthetic esthetic appeal, thethe appeal, colorant colorant provides provides product product
15 identification. 15 identification, Suitable Suitable colorants colorants include include those those approved approved and certified and certified by the by the FDA, FDA, including FD&C including FD&C and D&C andD&C approved approved dyes, dyes, lakes, andpigments, lakes,and titanium andtitanium pigments,and dioxide, provided dioxide, thatthe providedthat filmcoat thefilm containsnono coatcontains coordinating coordinating metals, metals, or only or only an an coordinating amountofofcoordinating amount metal metal approximately equal equal approximately to or than to or less than 0.025 less 0.025 parts parts of of B. CompoundB. Compound
20 20 the colorant Suitably, the Suitably, comprises colorant comprises or or oneone more more coloring coloring agents agents selected selected from from the group the rediron consistingofofred groupconsisting oxides,redreddyes ironoxides, andand dyes lakes, lakes, yellow iron iron yellow oxides, oxides,
dyesandand yellowdyes yellow titanium lakes,titanium lakes, dioxide, andand dioxide, indigo indigo carmine. carmine. For example, For example, the the colorant selectedto toprovide maybebeselected colorant may provide a light a light beige beige shade, for for shade, example example consisting consisting
essentially of essentially of a) iron oxide, red iron a) red red dye, oxide, red dye, and/or lake, b)b) yellow redlake, and/orred ironoxide, yellowiron yellow oxide,yellow 25 25 dye, and/or yellow dye, and/or c) c) lake,andand yellowlake, titanium titanium dioxide, dioxide. Alternatively, Alternatively, the colorant the colorant may may be be to provide selected to selected shade(e.g., pinkshade provideaapink essentiallyofoftitanium consistingessentially (e.g.,consisting andand dioxide titaniumdioxide red iron red iron oxide, red dye oxide, red and/orred dyeand/or lake);a alight redlake); shade greenshade lightgreen (e.g., consisting (e.g., consisting essentially of yellow essentially of yellow iron yellowdyedye oxide,yellow ironoxide, and/or and/or yellow yellow lake, lake, indigo indigo carmine, carmine, and and dioxide);a alight titanium dioxide); titanium light blue shade(e.g., blueshade essentiallyofoftitanium consistingessentially (e.g., consisting dioxide titaniumdioxide 30 and and 30 indigo indigo carmine); or an or carmine); an orange orange shade (e.g., (e.g., consisting shade consisting of essentially of essentially of titanium of titanium
andsunset dioxide and dioxide yellow). sunsetyellow).
- 15 -
04 Apr 2016
The Theabove mentioned abovementioned colorants that that colorants contain contain a coordinating metal metal a coordinating are are acceptable at a level approximately equal acceptable at a level approximately equal or or to to less less than than 0.025 0.025 parts parts of Compound of Compound B. B. In suitable In suitable alternative embodiments, alternative embodiments, thethe aqueous film film aqueous coating coating composition composition
for use for use in the current in the current invention comprises: invention comprises: 55 (i) (i) aa cellulosic film-formingpolymer; cellulosic film-forming andand polymer; (ii) (ii) a plasticizer. a plasticizer. 2016202063
Suitably, such compositions Suitably, such compositions further further comprise comprise a colorant. Such Such a colorant. compositions compositions
mayoptionally may furthercomprise optionallyfurther one one comprise or more or more additional additional adjuvants such assuch adjuvants a as a detackifier, flow detackifier, aid, surfactant, flow aid, film-forming secondaryfilm-forming and secondary surfactant, and polymer. polymer.
10 10 Examples Examples of of optional detackifiers detackifiers optional include include lecithin, lecithin, stearic stearic acid, mineral acid,mineral oil, oil,
modified derivatizedstarch, modifiedderivatized dextrin,andand tapiocadextrin, starch,tapioca polyethylene polyethylene glycol, glycol. Examples Examples of of optional secondary optional film-forming secondaryfilm-forming polymers polymers include sodiumsodium include alginate, alginate, propylene propylene
glycol glycol alginate, alginate, and polyvinylpyrrolidone. and polyvinylpyrrolidone. Examples Examples of optional of optional surfactants includeinclude surfactants sodiumsulfosuccinate dioctyl sodium dioctyl andand sulfosuccinate polysorbate polysorbate 80. Examples 80. Examples of optional of optional flow flow aids aids 15 15 talc, fumed include talc, include furned silica, bentonite, hydrogenated silica, bentonite, vegetable hydrogenated vegetable oils, stearines,andand oils,stearines, waxes. waxes.
aqueous Theaqueous The film film coat coat composition will will composition typically typically comprise comprise from 5%about from about to 5% to about 25%,suitably about 25%, 5% 5% about suitablyabout to about 20%, 20%, to about coating coating in the in solidssolids the vehicle. vehicle. In In suitable embodiments, suitable embodiments, thethe solids solids typically typically comprise comprise from from 25% to25% aboutabout aboutto70%, about 70%, 20 20 suitably 60% to about60% suitably about about7/0% to about film-forming polymer, 70% film-forming about 5% polymer, about 5% to about 10%, to about 10%,
about6%6% suitably about suitably to to about 8%,8%, about plasticizer, andand plasticizer, about 20% 20% about to about to about 35% colorant, 35% colorant, by by weight. weight.
A number A numberof of suitable suitable aqueous filmfilm aqueous coating coating compositions compositions are commercially are commercially
available. The available. aqueous Theaqueous coatcoat filmfilm composition may bemay composition be provided provided in the form of form in the a of a 25 25 solution or dispersion. solution or Alternatively,thethecomposition dispersion. Alternatively, may may composition be provided be provided in in a dry a dry canbebecombined that can formthat form combined the the withwith vehicle vehicle components components according according to supplier to supplier
instructions prior instructions to coating prior to the tablet. coating the aqueousfilm Suitably, aqueous tablet. Suitably, coating filmcoating compositions compositions
are those are commercially those commercially fromfrom available available Colorcon, Colorcon, Inc. of Point,Point, of West Inc.West PA, under under PA, the the trade name trade OPADRY and and name OPADRY OPADRY OPADRY 11 (nonlimiting II (nonlimiting examples examples include include Opadry Opadry YS- YS 1-7706-G 30 1-7706-G 30 white, white, Opadry Opadry Yellow Yellow 03B92357, 03B92357, Opadry Opadry Blue 03B90842). Blue 03B90842). These These availableas as compositionsareareavailable compositions drydry film film coating coating compositions compositions that can be diluted that becandiluted in in shortlybefore water shortly water use.OPADRY beforeuse. andOPADRY OPADRY and OPADRY II formulations II formulations comprise comprise a a
- 16-
04 Apr 2016
cellulosic film forming cellulosic film polymer formingpolymer (e.g.,HPMC (e.g., and may and HPC), HPC), and/orand/or HPMC may contain contain polydextrose, maltodextrin, a plasticizer polydextrose, maltodextrin, (e.g., triacetin, a plasticizer(c.g., glycol), polyethyleneglycol), triacetin, polycthylene polysorbate 80, polysorbate 80,a acolorant (e.g., titanium colorant(e.g., dioxide,one titaniumdioxide, more oneor ormore dyes dyes or lakes), or lakes), and/or and/or
other suitable other suitable film-forming polymers film-formingpolymers (e.g., (e.g., acrylate-methacrylate acrylate-methacrylate copolymers). copolymers).
5 5 OPADRY or or Suitable OPADRY Suitable OPADRY OPADRY II formulations may may If formulations comprise comprise a plasticizer a plasticizer oneone andand
or more maltodextrin,andand or more ofofmaltodextrin, polydextrose polydextrose (including (including butlimited but not to a) to not limited a) triacetin triacetin 2016202063
maltodextrin polydextroseor ormaltodextrin and polydextrose and or lactose, or lactose, b) b) or or polyethylene polyethylene glycol glycol and and maltodextrin). polydextroseorormaltodextrin). polydextrose
Thetablets The also suitably are also tablets are providea auniform coatedtotoprovide suitably coated uniform coating coating without without
10 speckling. 10 speckling. The tablets The tablets are typically coatedcoated are typically to provide to provide a dry tablet a dry tablet gain of gain weight weight of from about5%,5%, about2 2totoabout from about suitably suitably about about to 4%. 3 to3 4%.
Theuncoated The tabletcores uncoatedtablet areare cores coated coated with the the with aqueous film film aqueous coating coating
compositionbyby composition methods well well methods in the in knownknown art art using theusing commercially availableavailable commercially (e.g., Thomas equipment (c.g., equipment Thomas Acccla-Cota, Hi-Coater, Compu-Lab Acccla-Cota, Vector Hi-Coater, 36). InIn Compu-Lab 36).
15 the the general, 15 general, process process usually usually involves involves rolling rolling or tumbling or tumbling the tablets the tablets in a orpan, in a pan, or suspending tabletsonona acushion suspendingthethetablets cushion airair of of (fluidized bed),andand (fluidizedbed), intermittently intermittently or or continuously continuously) (preferablycontinuously) continuously(preferably spraying spraying a fine mist mist a fine of atomized of atomized droplets droplets of of the composition coating composition the coating onto thethe onto tablets,thethedroplets tablets, droplets wetting, wetting, spreading spreading and and coalescingononthe coalescing thetablets surfaceofofthe thesurface andand adherent formananadherent tabletstotoform coherent coherent film film 20 20 coating. aretypically tabletsare Thetablets coating. The typicallyheated to to 40 40 about heatedtotoabout °C,'C, 50 50 suitably suitably about about 45 45 to to
50 °C, 50 e.g., by 'C, e.g., air having by air 75 75 about temperatureofofupuptotoabout having aa temperature °C,*C, suitably suitably about about 6570to 65 to 70 0C. °C.
making Process ofofmaking Process thethe tablet tablet
tabletsofofthetheinvention Pharmaceuticaltablets Pharmaceutical thatarearewet-granulated inventionthat can can wet-granulated be be 25 25 preparedbybya aprocess prepared processcomprising the the comprising steps steps of: of: f) I) preparingthe preparing which granules;which thegranules; comprises comprises the steps the steps of: of: a) a) mixing togetherthethedrydrymaterials mixingtogether materials comprising comprising eltrombopag eltrombopag olamine, olamine, a a binder, and diluent, aa binder, diluent, optionally aa disintegrant and optionally foraa time disintegrantfor sufficient toto timesufficient homogenize homogenize thethe materials; materials;
30 30 b) b) addinga agranulating adding granulatingfluid mixtureof of themixture fluidtotothe dry materials, drymaterials, preferably preferably
while mixing; while mixing;
- 17-
2016202063 04 Apr 2016
c) c) mixing the granulating fluid mixing the granulating fluidwith thethe with mixture mixture of dry of dry materials for for materials a a granulating granulating time timesufficient uniformly generallyuniformly sufficienttotogenerally wetwet dry dry the the
so as materials, so materials, as to form wet to form granules; wetgranules;
d) d) wet-millingthe wet-milling granules; wetgranules; thewet
5 5 e) c) drying the wet-milled granules to to drying the wet-milled granules form dry dry form granules; granules; and and dry milling the dry granules to form granules of of desired size; desired size; f) f) dry milling the dry granules to form granules 2016202063
11) II) preparing thetablet; preparingthe the the comprises whichcomprises tablet; which steps of: of: steps a) a) mixing mixingthe thegranules granulesprepared in step prepared I) 1) in step 0 f) with external withexternal excipients excipients
10 10 comprising comprisinga afiller, filler, aa lubricant lubricant and for aa time disintegrantfor and aa disintegrant sufficient timesufficient
homogenize to homogenize to thethe granules and and granules external external excipients; excipients; and and
b) b) compressingthethe compressing mixture mixture comprising comprising the granules the granules and external and external
forma atablet. to form excipients to excipients tablet.
15 15 Suitably, Suitably, the the tablets are further tablets are film-coated, especially further film-coated, aqueous especially aqueous film-coated. film-coated.
In preparing In wet-granulated preparing wet-granulated granules, drydry thethe granules, materials may may materials be mixed be mixed with with suitable suitable equipment as as such equipmentsuch known known in art in the art (e.g., the (e.g., Niro-Fielder Niro-Fielder Blender/Granulator, Blender/Granulator,
Bear BearVarimixer, Varimixer,KeyKey ShearShear HighHigh Mixer/Granulator) Mixer/Granulator) for a time a time sufficient for sufficient to to
homogenize homogenize thethe materials, materials, e.g.,forforabout e.g., about 3 minutes. 3 minutes.
20 20 The granulatingfluid Thegranulating added thenadded fluidisisthen to to thedrydry the mixture, mixture, preferably preferably while while
The mixing.The mixing. granulating granulating fluid fluid is suitably is suitably water, water, although may may although alternatively alternatively be be
comprisedofof comprised water in in water withwith admixture admixture one or or more onemore of binders of binders PVP as such assuch andPVP and HPMC, HPMC, from about from 10 v/w% about to 30 to about 10 v/w% of v/w% v/w% 30 about of the granulating the granulating fluid, fluid, based based on the on the
total wet total mixture,isissuitably granulation mixture, wet granulation used.TheThe suitablyused. granulating granulating fluid and and fluid dry dry
25 25 materials mixed maybebemixed materials may using using suitable suitable equipment equipment such such as known known as in the art the art in (e.g., (e.g., Niro-Fielder Blender/Granulator, Niro-FielderBlender/Granulator, BearBear Varimixer, Varimixer, Key High High KeyShear Shear Mixer/Granulator)forfor Mixer/Granulator) a total sufficienttotogenerally timesufficient a totaltime wet wet uniformly generallyuniformly the the dry dry material material SO to form as to so as wetgranules, formwet about suitablyforforabout granules,suitably 3 to 3 to about about 15 minutes. 15 minutes.
Typically Typicallythe thefluid thedry addedtotothe fluid isis added materialwith drymaterial overover mixing withmixing a period a period of about of about I 1
30 30 to about 1515minutes, to about thenthethetotal minutes,then batchisismixed totalbatch mixed an an forfor additional additional time time (post (post-
granulating time),ofofabout fluid-additiontime), granulating fluid-addition to to minutes about0.50.5minutes about about 6 minutes. 6 minutes.
18 -
2016202063 04 Apr 2016
In a suitable embodiment, about In a suitable embodiment, 10 v/w% 10 v/w% about to about to about 30 v/w% v/w% granulating 30granulating fluid fluid granulating and a post-granulating fluid-addition granulating and a post-granulating fluid-addition time time of about of about 6 minutes 6 minutes or less or less is is used. Suitably, about 2424 v/w % granulating v/w and aand fluidfluid % granulating post-granulating fluid- fluid a post-granulating used. Suitably, about addition granulating timeofofless granulatingtime than3 3minutes lessthan is is minutes used, used, e.g.,about e.g., 2.52.5 about minutes. minutes. addition 55 Suitably, about 1616v/w% Suitably, about v/w%granulating and and fluidfluid granulating a post-granulating a post-granulating fluid-addition fluid-addition
granulating more timeofofmore granulatingtime than 2.52.5 than minutes minutes is used, is used, e.g., e.g., about about 4 minutes. 4 minutes. 2016202063
The wet wetgranules then granulesarearethen wet-milled wet-milled by methods by methods such as are as such known the in the known are in The art for providing aa generally art for providing uniformly generally uniformly sized wetwet sized mass that that (such(such mass the granules the granules dry dry relatively evenly). Suitable relatively evenly). wet-milling Suitablewet-milling techniques may may techniques involve involve screening screening (e.g., (e.g., 10 10 manual manualscreens), screens),comminuting (such(such millsmills comminuting as a Co-mil, as a Co-mil, including but notbut including not limited limited to a to a 0.375"screen), 0.375" extruders. screen),ororextruders. Thewet-milled The areare granules wet-milledgranules dried dried by methods by methods such such as are known areasknown in the in the art art for providing generally for providing uniform generallyuniform drying, drying, to a a low to low residual residual amount amount of granulating of granulating fluid fluid (preferably about (preferably 0.5% about0.5% to to about about 1.0%). FluidFluid 1.0%). bed dryers bed dryers are suitable dryingdrying are suitable 15 equipment. 15 equipment. driedgranules Thedried The dry-milled thendry-milled granulesarearethen using using known known methods methods to provide to provide
generally uniformly generally granules sizedgranules uniformlysized (unimodal (unimodal distribution), distribution), suitably suitably having a meana having mean particle diameter particle ofless diameter of than 240 less than microns 240microns (found (found to provide to provide improved improved content content
dry-milling Suitabledry-milling uniformity). Suitable uniformity). equipment equipment includes includes Co-mils, Co-mils, including but notbut including not 20 to to limited 20 limited havinga a0.094" having screen. 0.094"screen. Suitably the Suitably andthethedrydrymaterials granulesand the granules thethe of of materials compression compression mix mix are are ordertotofacilitate generally unimodal in size distribution, ininorder generally unimodal in size distribution, a formationofofa facilitate formation homogeneous homogeneous mix mix to mitigate andmitigate and to possible possible segregation mixthe of the of segregation after after blending. mixblending. If If drymaterials thedry necessary, the necessary, materialsmay be be may pre-screened pre-screened to provide to provide the desired the desired particle particle size size 25 25 distribution. lubricantmaymay Screeningofofthethelubricant distribution. Screening be particularly be particularly useful useful to deagglomerate to deagglomerate
lubricant. the lubricant. the
In preparing In compression thecompression preparing the mixture, the the mixture, granules, granules, filler, andand filler, disintegrant disintegrant
mixedover are mixed are suitableperiod overa asuitable of of period time, time, about about 5 to 15 15 5 to minutes, minutes. Lubricant Lubricant is is then then addedand added for for mixed andmixed a suitable a suitable period period of time, of time, about about 4 minutes. 1 to I4tominutes. The mixture The mixture is is 30 30 thenthen compressed compressed into tablets into tablets using presses such assuch using presses are known the artrotary the artin(e.g., as areinknown (e.g., rotary tablet press). tablet press).
-19-
2016202063 17 Jul 2024
It has been found that the above granulating fluid levels, granulating times, It has been found that the above granulating fluid levels, granulating times,
and excipients and excipients provide improvedprocessing. provide improved processing.
Capsules Capsules
Thechoice The choiceof of particular particular types types and and amounts ofexcipients, amounts of excipients, and capsulation and capsulation 2016202063
technique employed technique employeddepends depends on on thethe further further propertiesofofeltrombopag properties eltrombopag olamine olamine and and
the excipients, e.g., compressibility, flowability, particle size, compatibility, and the excipients, e.g., compressibility, flowability, particle size, compatibility, and
density. The density. Thecapsules capsulesmay maybebeprepared prepared according according to to methods methods known known in art, in the the art, suitably suitably filling fillinga standard two a standard twopiece piecehard hardgelatin gelatincapsule with capsule eltrombopag with eltrombopag olamine olamine
admixed with excipients, suitably filling a standard two piece hard gelatin capsule admixed with excipients, suitably filling a standard two piece hard gelatin capsule
with granules prepared according to this invention, suitably on a scale suitable for with granules prepared according to this invention, suitably on a scale suitable for
commercialproduction. commercial production.Suitable Suitable capsules capsules ofof theinvention the inventioncomprise comprise granules granules
comprisingeltrombopag comprising eltrombopag olamine olamine andand oneone or more or more of fillers,binders of fillers, bindersand and disintegrants, wherein the granules are mixed with additional filler, binder, disintegrants, wherein the granules are mixed with additional filler, binder,
disintegrant and/or lubricant to form a granular mixture that is filled into capsules. disintegrant and/or lubricant to form a granular mixture that is filled into capsules.
Included in Included in the the present present invention invention are are pharmaceutical compositionsinin pharmaceutical compositions
capsule form, capsule form, suitably suitably prepared on aa commercial prepared on commercialscale, scale,that that comprise compriseeltrombopag eltrombopag olamine, wherein the capsule is made using a diluent or diluents that are olamine, wherein the capsule is made using a diluent or diluents that are
substantially free of coordinating metals and/or that are substantially free of substantially free of coordinating metals and/or that are substantially free of
reducing sugars. reducing sugars. Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe capsule capsule is is made, made, suitably suitably on on a a commercial scale, using a diluent or diluents that are substantially free of commercial scale, using a diluent or diluents that are substantially free of
coordinating metals and/or that are substantially free of reducing sugars, and the coordinating metals and/or that are substantially free of reducing sugars, and the
eltrombopagolamine eltrombopag olamine particleshave particles havea aparticle particle size size range range in in which X90isis greater which X90 greater than 10 than micronbut 10 micron butless less than than 90 micron. 90 micron.
Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe capsule capsule is is made, made, suitably suitably on on a a commercial scale, using a diluent or diluents that are substantially free of commercial scale, using a diluent or diluents that are substantially free of
coordinating metals and/or that are substantially free of reducing sugars, and the coordinating metals and/or that are substantially free of reducing sugars, and the
eltrombopagolamine eltrombopag olamine particleshave particles havea aparticle particle size size range range in in which X90isis greater which X90 greater than 10 micron but less than 90 micron, suitably greater than 20 micron but less than 10 micron but less than 90 micron, suitably greater than 20 micron but less
than 50 than micron. 50 micron.
- 20 -
2016202063 17 Jul 2024
Also included Also includedin in the the present present invention invention are are pharmaceutical compositionsthat pharmaceutical compositions that compriseeltrombopag comprise eltrombopag olamine, olamine, wherein wherein thethe capsule capsule is is made, made, suitably suitably on on a a commercial scale, using a diluent or diluents that are substantially free of commercial scale, using a diluent or diluents that are substantially free of
coordinating metals and/or that are substantially free of reducing sugars, and the coordinating metals and/or that are substantially free of reducing sugars, and the
eltrombopagolamine eltrombopag olamine particleshave particles havea aparticle particle size size range range in in which X50isis greater which X50 greater 2016202063
than 5 micron but less than 50 micron, suitably greater than 5 micron but less than than 5 micron but less than 50 micron, suitably greater than 5 micron but less than
20 micron. 20 micron. Theinvented The inventedgranules granulesand andsolid solidoral oral pharmaceutical pharmaceuticaldosage dosageforms forms may may be be administered administered in in therapeutically therapeutically effective effective amounts amounts toortreat to treat or prevent prevent a diseasea state, disease state, e.g., as described in the above referenced International Applications Nos. e.g., as described in the above referenced International Applications Nos.
PCT/US01/16863,PCT/US03/16255 PCT/US01/16863, PCT/US03/16255andand PCT/US04/013468, PCT/US04/013468, the the disclosuresofof disclosures
which are herein incorporated by reference. It will be recognized by one of skill in which are herein incorporated by reference. It will be recognized by one of skill in
the art that the optimal quantity and spacing of individual dosages of eltrombopag the art that the optimal quantity and spacing of individual dosages of eltrombopag
olamine formulationsofofthe olamine formulations the invention invention will will be be determined determinedbybythe thenature nature and andextent extent of the condition of the conditionbeing being treated treated and and the particular the particular patient patient being being treated, treated, and and that that such such
optimums canbebedetermined optimums can determined by by conventional conventional techniques. techniques. It will It will alsoalso be be
appreciated by one of skill in the art that the optimal course of treatment, i.e., the appreciated by one of skill in the art that the optimal course of treatment, i.e., the
numberofofdoses number dosesofofeltrombopag eltrombopag olamine olamine given given perper dayday forfor a defined a defined number number of of days, can be ascertained by those skilled in the art using conventional course of days, can be ascertained by those skilled in the art using conventional course of
treatment determination tests. treatment determination tests.
A method A methodofofthis this invention inventionof of inducing inducingTPO TPO agonistactivity agonist activityinin humans humans comprises administering to a subject in need of such activity a therapeutically comprises administering to a subject in need of such activity a therapeutically
effective amount effective of aa solid amount of solid oral oralpharmaceutical pharmaceutical dosage formofofthe dosage form the present present invention. invention.
Theinvention The inventionalso also provides provides for for the the use use of of eltrombopag olamineininthe eltrombopag olamine the manufactureofofaasolid manufacture solid oral oral pharmaceutical dosageform pharmaceutical dosage formofofthe thepresent presentinvention. invention. Theinvention The inventionalso also provides provides for for the the use use of of eltrombopag olamineininthe eltrombopag olamine the manufactureofofaasolid manufacture solid oral oral pharmaceutical dosageform pharmaceutical dosage formofofthe thepresent presentinvention inventionfor for use in enhancing platelet production. use in enhancing platelet production.
Theinvention The inventionalso also provides provides for for the the use use of of eltrombopag olamineininthe eltrombopag olamine the manufactureofofaasolid manufacture solid oral oral pharmaceutical dosageform pharmaceutical dosage formofofthe thepresent presentinvention inventionfor for use in use in treating treatingthrombocytopenia. thrombocytopenia.
-- -21 -
04 Apr 2016
The invention also provides for a solid oral pharmaceutical dosage form for use as a The invention also provides for a solid oral pharmaceutical dosage form for use as a
TPO TPOmimetic which mimetic comprises which eltrombopag comprises olamineolamine eltrombopag and a pharmaceutically acceptableacceptable and a pharmaceutically carrier of the present invention. carrier of the present invention.
invention also The invention The also provides for aa solid provides for oral pharmaceutical solid oral dosage form pharmaceutical dosage useinin foruse formfor 55 thethe treatment of thrombocytopenia treatmentof thrombocytopenia which which comprises comprises eltrombopag cltrombopag olamine olamine and a and a
pharmaceutically acceptable carrier of the present invention. pharmaceutically acceptable carrier of the present invention.
oral pharmaceutical formfor dosage form useinin foruse 2016202063
The The invention invention also provides for also provides solid oral for aa solid pharmaccutical dosage
enhancing enhancing platelet production platelet comprises whichcomprises production which eltrombopag eltrombopag olamine olamine and a and a
pharmaceutically acceptable pharmaceutically acceptable carrier of theof carrier the present present invention. invention.
10 10 The The invention invention also providesa process alsoprovides forfor a process preparing preparing solid oraloral solid pharmaceutical pharmaceutical
dosage dosage forms a diluentor or containinga diluent formscontaining diluents diluents are are thatthat substantially freefree substantially of of
coordinating metals coordinating that are and/or that metals and/or of reducing free of substantially free are substantially reducing sugars and aa sugars and
therapeutically effective therapeutically of eltrombopag amount of effectiveamount eltrombopag olamine, processcomprises whichprocess olamine, which bringing comprisesbringing
olamineinto eltrombopagolamine eltrombopag association with intoassociation the diluent with the diluent or diluents. or diluents. 15 15 No unacceptable No unacceptabletoxicological effectsareareexpected toxicologicaleffects whenwhen expected the compound the compound of the of the invention is administered in accordance with the present invention. invention is administered in accordance with the present invention.
Withoutfurther Without elaboration, furtherelaboration, it believed it is that that is believed one skilled in theinart one skilled art thecan, can, using using the thepreceding preceding description, description, utilize the the utilize present present invention to its to invention its fullest fullest extent. extent.
The Thefollowing Examples, followingExamples, therefore, therefore, are to be construed arebeto construed as merely as merely illustrative illustrative and and not not
a limitation 20 a limitation 20 of the of the scope scope of the the present of present invention. invention.
the excipients All the All recipients utilized standard herein arearestandard utilized herein pharmaceutical gradegrade pharmaceutical excipients availablefrom excipients available numerous fromnumerous manufacturers manufacturers well to well known inthose those to known in the the art. art.
- 22 -
2016202063 04 Apr 2016
Examples Examples
Examples Examples I to 1 to 7--Tablet 7--Tablet preparation preparation
5 5 Wet Wetgranulated, granulated,tablets tabletscomprising comprising eltrombopag eltrombopag olamine and theand olamine the ingredients ingredients
Table 1I were in Table in prepared. wereprepared. 2016202063
Table 1 I Table
Component/Tablet Strength ComponenfTabletStrength 12.5 12.5 25 25 25 25 1 50 50 50 50 75 75 100 100 Mg mE Mg mg mg Iimg mg mg mg mg mg mg mg mg Granules 40% Granules Drug-loaded 40% Drug-loaded (39.9) (39.9) (79.7) (79.7) (79.7) (159.4) (159.4) (79.7) (159.4) (239. 1) (318.8) (159.4) (239.1) (318.,) eltrombopag olamine, milled eltrombopag olamine, milled 15.95 15.95 31.9 31.9 31.9 31.9 63.8 63.8 63.8 63.8 95.7 95.7 127.6 127.6
Microcrystalline cellulose Microcrystalline cellulose 7.45 7.45 14.9 14.9 14.9 14,9 29.8 29.8 29.8 29.8 44.7 44.7 59.6 59.6
Mannitol Mannitol 14.9 14.9 29.7 29.7 29.7 29.7 59.5 59.5 59.5 59.5 89.2 89.2 118.9 118.9
Povidone Povidone 1.6 1.6 3.2 3.2 3.2 3.2 6.4 6.4 6.4 6.4 9.6 9.6 12.8 12.8
Purified water Purified water - - - - - - -
E'ra-granular Extra-granular components components
Microcrystalline cellulose Microcrystalline cellulose 1194 119.4 238.8 238.8 238.8 238.8 159.1 159.1 1591 159.1 79.3 79.3 NA NA Sodiumstarch Sodium glyclate starchglycolate 14.0 14.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0 27.6 27.6
Stearate MagnesiumStearate Magnesium 1.75 1.75 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
m- components etng components Film-coating _
Purified water Purified water --_ - - -
white Opadry@white Opadry® 8.9 8.9 14.0 14.0 14.0 14.0 14.0 14.0
Orange Opadry Orange Opadry 14.0 14.0
Oadry Brown Opadry Brown 14,0 14.0
Opadry Blue Opadry Blue 14.0 14.0
Total tablet weight (mg/tablet) Total tablet weight (mg/tablet) 183.9 183.9 364 364 364 364 364 364 364 364 364 364 364 364 10 10
Granules were Granules were prepared prepared by separately by separately weighing weighing and screening and screening mannitol, mannitol,
celluloseand microcrystallinecellulose microcrystalline povidone. andpovidone.
As aa general As procedure,thethe general procedure, ingredients ingredients were were blended with with blended the active the active
ingredient and ingredient thenwet-granulated andthen (in (in wet-granulated a high-shear a high-shear wet-granulator) with with wet-granulator) purified purified
15 15 water. Thewet-granule water. The massmass wet-granule was wet-milled, was wet-milled, then dried dried then in in a fluid-bed a fluid-bed dryer and theand dryer the
dried granules dried granuleswere milled. weremilled.
extragranular Thenextragranular Then ingredients ingredients (microcrystalline (microcrystalline cellulose, cellulose, if needed, if needed, and and sodium sodiumstarch were glycolate)were starchglycolate) separately separately weighed, weighed, screened screened and blended with thewith and blended the granules. Magnesium granules. Magnesium stearate added and was added stearate was with the blended with and blended The blend mixture. The the mixture.
- 23 -
2016202063 04 Apr 2016
was compressed and the tablet cores was compressed and the tablet werewere cores film film then then coated. coated. The tablets The tablets were were film film
coated with coated aqucous suspension an aqueous with an ofOPADRY suspension of filmcoating OPADRY film preparation. coatingpreparation.
Example 8 Tablet Example 8 Tablet Preparation Preparation 2016202063
5 5 Eltrombopag Eltrombopag olamine olamine tablets tablets containing containing diluents with with diluents the coordinating the coordinating metal metal calcium phosphate calciumphosphate dibasic dibasic anhydrous were were anhydrous manufactured manufactured in a similar in a similar manner manner as as described above. described above.Tablet composition composition Tablet for the the tablet fortablet coordinating coordinating diluentdiluent metal metal is is table2.2. providedinintable provided
10 10 Table22 Table
Component/Tablet Component/Tablet Strength Strength 50 mg 50 mg
Granules40% Granules Driu-loaded 40%Drug-loaded (159.4) (159.4)
eltrombopag olamine, eltrombopag milled olamine, milled 63.8 63.8 Calcium Phopshate Calcium dibasic anhydrous Phopshate dibasic anhydrous 89.3 89.3 Povidone Povidone 6.4 6.4
Purified water Purified water I Extra-granular components Extra-granular components cellulose Microcrystallinecellulose Microcrystalline 159.1 159.1
Sodiumstarch Sodium glycolate starchglycolate 28.0 28.0 Stearate3. MagnesiumStearate Magnesium 3.5
Film-coatingcomponents Film-coating components Purified water Purified water -
white Opadry@white Opadry® 14.0 14.0
Total tablet Total tablet weight (mg/tablet) weight (mg/tablet) 364
- 24 -
C NRPo DCC\KXG06V _i-DOCf/2/2ii2
2016202063 04 Apr 2016 04 Apr 2016
In figure 1, the tablet prepared with no coordinating metal diluent (indicated as In figure 1, the tablet prepared with no coordinating metal diluent (indicated as
"with "with non-coordinating is aa eltrombopag diluent") is metaldiluent") non-coordinating metal eltrombopag 50 tablet generally 50mgmgtablet prepared generally prepared as described in Table I above and the tablet prepared with the coordinating metal diluent as described in Table 1 above and the tablet prepared with the coordinating metal diluent - -
5 5 Calcium Phopshate Calcium dibasic dibasic Phopshate anhydrous anhydrous - (indicated - (indicated as "with as "with co-ordinating co-ordinating metal metal diluent") diluent")
generally prepared tablet generally mgtablet as described prepared as in Table described in 2 above. Table 2 2016202063
is aaeltrombopag is 50 mg eltrombopag 50 above.
Dissolution comparison Dissolution performed wasperformed comparisonwas using USPUSP using Apparatus Apparatus II, 50 50 rpm, II,rpm, in phosphate in phosphate
buffer pH buffer 6.8 containing pH 6.8 Tween 0.5% Tween containing 0.5% 80.80.
10 10 Example 99 Example
Figure 2 depicts the effect of API particle size distribution on eltrombopag olamine Figure 2 depicts the effect of API particle size distribution on eltrombopag olamine
dissolution. Eltrombopag dissolution. Eltrombopag olamine 75mg olamine75mg tablets tablets were were generally generally prepared prepared in the in the manner manner
described in Example 5, using different particle sizes. The particle size refers to the described in Example 5, using different particle sizes. The particle size refers to the
15 particle size of the drug granules used in the formulation. 15 particle size of the drug granules used in the formulation.
Dissolution comparison Dissolution performed wasperformed comparisonwas using USPUSP using Apparatus Apparatus II, 50 50 rpm, II,rpm, in phosphate in phosphate
buffer pH buffer 6.8 containing pH 6.8 Tween 0.5% Tween containing 0.5% 80.80.
20 20
The reference in this specification to any prior publication (or information derived from it), The reference in this specification to any prior publication (or information derived from it),
or to any or to matter which any matter which isis known, is not, known, is not be should not and should not, and be taken as an taken as acknowledgment oror anacknowledgment
formform anyany admission or or admission of suggestion of suggestion that that prior publication that publication thatprior (or information (or information derived derived from from it) it) oror known matter forms known matter part of forms part the common of the common general knowledge generalknowledge in the in the fieldofof field
25 endeavour 25 endeavour to which thisthis to which specification relates. specificationrelates.
Throughout this specification and the claims which follow, unless the context requires Throughout this specification and the claims which follow, unless the context requires
otherwise, the word otherwise, the word "comprise", variations such andvariations "comprise", and "comprises"and as "comprises" such as will "comprising",will and"comprising", be understood to imply the inclusion of a stated integer or step or group of integers or steps be understood to imply the inclusion of a stated integer or step or group of integers or steps
30 but but 30 the the not not exclusion of anyof exclusion other or step or other integer any integer of group group or or step of or integers steps. or steps. integers
-- 25